Profusa, Inc. Common Stock

Profusa has submitted a comprehensive response package to its European Notified Body GMED following successful completion of Stage 1 and Stage 2 assessments for CE Mark certification of its Lumee Oxygen Platform. The submission includes updates to technical documentation, quality system evidence, clinical evaluation activities, and validation inf...

Profusa, Inc. (PFSA) has been granted approval by the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. The company must satisfy interim milestones and comply with bid price and stockholders' equity requirements by July 6, 2026, to maintain its continued listing.

Profusa (NASDAQ: PFSA) shares plummeted 40.27% on Tuesday following the announcement of a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform for approximately $30 million in an all-equity deal. The acquisition marks Profusa's strategic expansion into molecular diagnostics and aims to complement its Lumee real-time ...

Profusa announced an all-equity acquisition of BioInsights LLC's PanOmics multi-omics diagnostics platform, expanding into precision diagnostics. The deal adds $30 million to shareholder equity and accelerates commercialization through integration with Profusa's Lumee platform. The company is also advancing a Mayo Clinic collaboration for pancrea...

Profusa announced a new distributor partnership with MedSell in France to commercialize its Lumee Oxygen tissue monitoring device for critical limb threatening ischemia (CLTI) patients. This partnership, combined with existing distributors across Europe, now covers approximately 200,000 annual CLI cases in the EU. The company projects $0.5-$2 mil...